Literature DB >> 21193223

The nuclear to cytoplasmic shift of ING5 protein during colorectal carcinogenesis with their distinct links to pathologic behaviors of carcinomas.

Hua-chuan Zheng1, Pu Xia, Xiao-yan Xu, Hiroyuki Takahashi, Yasuo Takano.   

Abstract

Inhibitor of growth 5, a tumor suppressor protein, can interact with p53, thereby inhibiting cell growth and inducing apoptosis. Inhibitor of growth 5 overexpression results in a reduction in colony-forming efficiency and cell population in S phase. To clarify the roles of inhibitor of growth 5 in tumorigenesis and progression of colorectal carcinomas, we examined inhibitor of growth 5 expression by immunohistochemistry on a tissue microarray containing colorectal carcinomas (n = 306), adenomas (n = 69), and nonneoplastic mucosa (n = 288) and compared this with clinicopathologic parameters of the carcinomas. In addition, inhibitor of growth 5 expression in colorectal carcinoma tissues and cell lines (DLD-1, HCT-15, SW480, and WiDr) was analyzed by Western blot and reverse transcriptase-polymerase chain reaction. It was found that the inhibitor of growth 5 protein was localized to the nuclei of colon carcinoma cells with no differences at mRNA levels. Among 18 frozen samples of colorectal carcinoma, significantly increased expression of inhibitor of growth 5 protein was observed in the carcinoma in comparison with adjacent mucosa in 14 cases (77.8%; P < .05), and 71.4% (10/14) of carcinoma cases exhibited up-regulated inhibitor of growth 5 mRNA expression. Decreased inhibitor of growth 5 expression was detected by immunohistochemistry in colorectal carcinoma, compared with non-neoplastic mucosa and adenoma (P < .05). Nuclear inhibitor of growth 5 expression was negatively correlated with tumor size, depth of invasion, degree of dedifferentiation, and Union Internationale Contre le Cancer staging (P < .05). In contrast, cytoplasmic inhibitor of growth 5 expression was positively correlated with depth of invasion, lymphatic invasion, and Union Internationale Contre le Cancer staging (P < .05). It was suggested that aberrant inhibitor of growth 5 expression may contribute to pathogenesis, growth, and invasion of colorectal carcinomas and could be considered as a promising marker to gauge aggressiveness of colorectal carcinomas. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193223     DOI: 10.1016/j.humpath.2009.12.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway.

Authors:  Qing-Ye Zhao; Fang Ju; Zhi-Hai Wang; Xue-Zhen Ma; Hui Zhao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  The pathobiological features of gastrointestinal cancers (Review).

Authors:  Xue Yang; Yasuo Takano; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2012-03-01       Impact factor: 2.967

3.  Expression profile of the REG gene family in colorectal carcinoma.

Authors:  Hua-chuan Zheng; Akira Sugawara; Hiroshi Okamoto; Shin Takasawa; Hiroyuki Takahashi; Shinji Masuda; Yasuo Takano
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

Review 4.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

5.  Epigenomics of Total Acute Sleep Deprivation in Relation to Genome-Wide DNA Methylation Profiles and RNA Expression.

Authors:  Emil K Nilsson; Adrian E Boström; Jessica Mwinyi; Helgi B Schiöth
Journal:  OMICS       Date:  2016-06

6.  The inhibitor of growth protein 5 (ING5) depends on INCA1 as a co-factor for its antiproliferative effects.

Authors:  Feng Zhang; Nicole Bäumer; Miriam Rode; Ping Ji; Tao Zhang; Wolfgang E Berdel; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2011-07-05       Impact factor: 3.240

7.  ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.

Authors:  Feng Zhang; Xutao Zhang; Jin Meng; Yong Zhao; Xinli Liu; Yanxia Liu; Yukun Wang; Yuhua Li; Yang Sun; Zhipeng Wang; Qibing Mei; Tao Zhang
Journal:  Oncotarget       Date:  2015-06-30

8.  ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.

Authors:  Wen-feng Gou; Dao-fu Shen; Xue-feng Yang; Shuang Zhao; Yun-peng Liu; Hong-zhi Sun; Rong-Jian Su; Jun-sheng Luo; Hua-chuan Zheng
Journal:  Oncotarget       Date:  2015-08-14

9.  Downregulated inhibitor of growth 3 (ING3) expression during colorectal carcinogenesis.

Authors:  Wen-feng Gou; Hong-zhi Sun; Shuang Zhao; Zhe-feng Niu; Xiao-Yun Mao; Yasuo Takano; Hua-chuan Zheng
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

10.  ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.

Authors:  Ulrike Linzen; Richard Lilischkis; Ruwin Pandithage; Britta Schilling; Andrea Ullius; Juliane Lüscher-Firzlaff; Elisabeth Kremmer; Bernhard Lüscher; Jörg Vervoorts
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.